Choice Institutional Equities has reiterated a 'Buy' rating on Marksans Pharma with a price target of INR 385. This outlook follows the company's strong Q2 FY27 results, which saw revenue grow over 30%. Investors are tracking the company's progress in international markets and its shift toward a branded prescription business model.
Choice Institutional Equities has reiterated its positive stance on Marksans Pharma, setting a price target of INR 385. This recommendation follows the company's recent Q2 FY27 financial results, where the business reported strong year-on-year growth. Consolidated revenue for the quarter rose by 30.5%, while EBITDA jumped by 48.3% and profit after tax increased by 43.9%.
Strategic Expansion and Revenue Goals
Marksans Pharma is currently aiming to reach INR 40 billion in revenue by the 2028 fiscal year. The company's growth strategy is supported by high demand in the United States and ongoing expansion efforts in Europe. Additionally, the company is pivoting toward a branded prescription business model in Australia. Analysts are watching the execution of this specific Australian strategy as a key component for long-term growth, as it marks a shift in the company's product focus.
Financial Position and Margins
The brokerage anticipates that EBITDA margins will stay in the 21.5% to 23% range in the near term. This stability is supported by higher facility utilization rates at its Teva site and a product mix that leans toward higher-margin offerings. From a balance sheet perspective, Marksans Pharma remains largely debt-free, which provides the company with significant financial flexibility compared to some peers in the pharmaceutical sector.
Sector Risks and Valuation
While the company has shown positive momentum, investors should consider the broader risks facing the pharmaceutical industry. Marksans operates in highly regulated international markets, which introduces constant regulatory compliance risks. The company also faces intense competitive pressure, particularly in its oral solid and over-the-counter (OTC) segments. Additionally, some market analysts have flagged the company's current valuation as high, suggesting that stock performance is pricing in strong growth expectations. Other factors, such as raw material cost fluctuations and the complexities of integrating inorganic growth or acquisitions, remain relevant for shareholders.
What Investors Should Monitor
Moving forward, the primary focus for market observers will be the company’s ability to execute its expansion plans without significant cost increases. Investors may want to track the quarterly progress of profit margins to see if the company can maintain its projected efficiency levels. Furthermore, updates on the transition of the branded prescription business in Australia and any developments regarding regulatory approvals in international markets will be essential to gauge if the company is on track to meet its long-term financial targets.